FDA Approves Device to Help Manage Infections in Organ Transplant Patients

The FDA has approved the first DNA test to help healthcare professionals gauge the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus antiviral therapy.

Advertisement

 

Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!

While a patient is undergoing anti-CMV therapy, a clinician can use the COBAS AmpliPrep/COBAS TaqMan CMV Test to look for changes in a patient’s CMV viral load. A significant decrease in viral load from one test to the next may indicate that a particular therapy is effective, while an increase or no change may indicate the need for a different therapy.

CMV is a common virus that can cause severe diseases such as pneumonia or colitis in people with weakened immune systems, including solid organ transplant patients.

More Articles on Infections:

TRICARE Patients See Fewer MRSA Infections

Consumer Reports Releases Hospital Safety Ratings

How Hospitals’ Data Transparency Can Spur Quality Improvement

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.